Clinical trials
Gastric or Esophagogastric Junction Adenocarcinoma clinical trials
Below are recruiting gastric or esophagogastric junction adenocarcinoma clinical trials, each written for real people, not researchers. We’re tracking 924 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07518147RecruitingPhase 3
BL-M05D1 for advanced stomach cancer after first treatment
This study tests a new antibody drug (BL-M05D1) for advanced stomach or lower esophagus cancer that did not respond to first-line chemotherapy. The drug targets a protein called claudin 18.2 found on some cancer cells and may help slow or shrink the cancer.
Beijing, Beijing MunicipalityAges 18–75 - NCT07462923RecruitingPhase 1
A study of HS-20093 for advanced stomach or gastroesophageal cancer
This trial tests a new drug, HS-20093, in people with advanced stomach or gastroesophageal junction cancer that has not responded to other treatments. The goal is to see if it can help shrink or slow the growth of the cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07431281RecruitingPhase 3
New drug combo for advanced stomach cancer with CLDN18.2
This trial tests a new drug combination for people with advanced stomach cancer that has not been treated before. It looks at two groups: one with PD-L1 (a protein that helps decide if immunotherapy works), and one without. The treatment includes an antibody-drug conjugate (Sonesitatug Vedotin) plus standard chemotherapy, with or without an immunotherapy drug.
Birmingham, AlabamaAges 18 years+ - NCT07392892RecruitingPhase 2/Phase 3
Study of PF-08634404 plus chemo for stomach and esophagus cancer
This trial tests a new study drug called PF-08634404 in combination with standard chemotherapy for people with stomach, gastroesophageal junction, or esophagus cancer that has spread. It aims to see if adding this drug helps the treatment work better.
Atascadero, CaliforniaAges 18 years+ - NCT06773312RecruitingPhase 1
Study of BC001 plus Sintilimab and XELOX for advanced stomach cancer
This trial tests a combination of three drugs (BC001, Sintilimab, and XELOX chemotherapy) for people with advanced or metastatic HER-2 negative stomach cancer or cancer where the stomach meets the esophagus. The goal is to see if this combination works better than standard treatments.
Beijing, Beijing MunicipalityAges 18–75 - NCT07118527RecruitingPhase 3
New drug combo for untreated advanced stomach cancer
This trial tests a new combination of an anti-HER2 drug (SHR-A1811) plus chemotherapy and an immunotherapy (adebrelimab) for people with untreated advanced stomach cancer. It aims to see if this combination works better than standard treatment.
Shenyang, LiaoningAges 18–75 - NCT07115485RecruitingPhase 2
Study of HLX43 for advanced stomach or junction cancer
This trial tests a new drug called HLX43 (an antibody-drug conjugate targeting PD-L1) for people with advanced stomach or gastroesophageal junction cancer that has progressed after at least one prior treatment. It aims to see if it can shrink tumors and help patients live longer.
BeijingAges 3 weeks–2 months - NCT05170503RecruitingPhase 2
Immunotherapy plus chemo before surgery for junction stomach cancers
This Phase 2 study tests giving immunotherapy together with chemotherapy before surgery for certain “locally advanced” cancers at the esophagus-stomach junction. It may help shrink the tumor and improve outcomes by treating the cancer earlier with both immune and chemotherapy approaches.
Guangzhou, GuangdongAges 18–75 - NCT06947291RecruitingPhase 2
Study of glumetinib plus nab-docetaxel for advanced stomach cancer
This trial tests a combination of two drugs, glumetinib and nab-docetaxel, in people with advanced stomach cancer or other solid tumors that have a specific change in the MET gene. The goal is to see if this combination is safe and works better than current treatments.
Hangzhou, ZhejiangAges 18 years+ - NCT06841679RecruitingPhase 2/Phase 3
Testing utidelone plus chemo for untreated stomach cancer
This trial tests a new capsule (utidelone) combined with standard chemotherapy as a first treatment for advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. It aims to see if this combination works better than current options.
Hialeah, FloridaAges 18 years+ - NCT06649292RecruitingPhase 3
Study of SHR-A1904 for gastric cancer with CLDN18.2
This trial tests a new drug called SHR-A1904 against standard treatments for people with advanced stomach or gastroesophageal junction cancer that has already been treated once. It is for those whose tumors are positive for a protein called CLDN18.2.
Guangzhou, GuangdongAges 18–75 - NCT05482893RecruitingPhase 1/Phase 2
Study of spevatamig for advanced gastrointestinal cancers
This trial tests a new drug called spevatamig (PT886) alone or with other treatments for advanced stomach, gastric, pancreatic, bile duct, or colorectal cancers. The goal is to see if it helps slow or stop cancer growth.
Duarte, CaliforniaAges 18 years+ - NCT07481357RecruitingPhase 1
DA 3501 for advanced stomach or pancreatic cancer
This trial tests a new drug, DA 3501, in people with advanced stomach or pancreatic cancer that has a specific protein called CLDN18.2. It aims to see if the drug is safe and effective.
Seongnam, BundangAges 19 years+ - NCT06962137RecruitingPhase 2
Zolbetuximab plus two chemos for CLDN18.2-positive stomach cancer
This trial tests a combination of three drugs (zolbetuximab, paclitaxel, and ramucirumab) for people with advanced stomach or esophagus cancer that has a specific protein called CLDN18.2. It may be an option if you've already had one standard treatment.
AntwerpAges 18 years+ - NCT06789172RecruitingPhase 1
New drug OKN4395 with or without pembrolizumab for solid tumors
This trial tests a new oral drug called OKN4395, which targets a COX2-related immune pathway, alone or with the immunotherapy pembrolizumab, in people with advanced solid tumors. It may be an option if you have certain types of cancer that have stopped responding to other treatments.
Beverly Hills, CaliforniaAges 18 years+ - NCT06038578RecruitingPhase 2
TRK-950 with standard chemo for advanced stomach cancer
This trial tests a new drug, TRK-950, added to standard chemotherapy (ramucirumab and paclitaxel) for people with advanced stomach or gastroesophageal junction cancer that has worsened after previous treatment. The goal is to see if this combination can help shrink tumors or slow disease progression.
Duarte, CaliforniaAges 18 years+ - NCT05365581RecruitingPhase 1
Study drug for stomach and pancreatic cancers with lab-checked targets
This Phase 1 trial tests ASP2138 alone or with other cancer medicines in adults with stomach (including GEJ) or pancreatic cancer. You may be eligible if your tumor has a specific protein marker and your health tests and scan results meet safety requirements.
Orange, CaliforniaAges 18 years+ - NCT04908566RecruitingPhase 2
PD-1 immunotherapy plus chemotherapy before and after gastric surgery
This trial studies whether adding a PD-1 immune therapy to chemotherapy around the time of surgery can improve outcomes for people with locally advanced stomach or stomach–esophagus junction cancer. It aims to better control the cancer before and reduce the chance it comes back after surgery.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT04989985RecruitingPhase 2
SOX chemotherapy plus immunotherapy for junction stomach-esophagus cancer
This trial studies whether adding an immunotherapy drug (sintilimab) to standard chemotherapy (S-1 and oxaliplatin) can better treat locally advanced cancer at the junction of the esophagus and stomach. It may help shrink the tumor and control the cancer before or around surgery.
Guangzhou, GuangdongAges 18–75 - NCT06163729RecruitingPhase 2
Testing camrelizumab plus chemo and radiation before/after surgery for stomach-esophagus cancer
This trial tests combining the immunotherapy drug camrelizumab with chemotherapy and radiation before and after surgery for a specific type of stomach-esophagus cancer. It aims to see if this approach helps shrink the tumor and improve outcomes.
Beijing, Beijing MunicipalityAges 18–80 - NCT07849608Recruiting
AI Tool to Assess Tumor Response After Pre-Surgery Treatment
This study is testing an AI tool (DeepTRG) that looks at tissue samples after pre-surgery treatment to see how well the tumor responded. It may help doctors better understand whether the treatment worked.
Shijiazhuang, None SelectedAges 18 years+ - NCT07751302Recruiting
Follow-up vs. chemo after surgery for early stomach cancer
This trial compares two approaches after surgery for early-stage stomach or GEJ cancer: close monitoring (follow-up) vs. adjuvant chemotherapy (chemo given after surgery). It aims to see if follow-up alone is as good as chemo for patients with this stage, potentially avoiding chemo side effects.
Xi'an, ShaanxiAges 18 years+ - NCT06644352Recruiting
Comparing right vs. left chest surgery for junction cancer
This study compares two surgical approaches (right side of the chest vs. left side of the chest) for removing a certain type of cancer at the gastroesophageal junction. It aims to find which approach leads to better outcomes.
BeijingAges 18–80 - NCT07673887RecruitingPhase 3
Study of a new drug combo for advanced stomach cancer
This trial tests a new drug called ASP2138 combined with chemotherapy and pembrolizumab for people with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. It may help if your tumor has certain markers (CLDN18.2 and PD-L1) and you haven't had prior chemotherapy for advanced disease.
Saint Louis Park, MinnesotaAges 18 years+
Hear when a new Gastric or Esophagogastric Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for gastric or esophagogastric junction adenocarcinoma?
- Yes. Clin2 currently lists 924 recruiting gastric or esophagogastric junction adenocarcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a gastric or esophagogastric junction adenocarcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a gastric or esophagogastric junction adenocarcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Gastric / Gastroesophageal Junction Adenocarcinoma
- Adenocarcinoma of Esophagogastric Junction
- Gastric or Gastroesophageal Junction Adenocarcinoma
- AFP Gastric or Gastroesophageal Junction Adenocarcinoma
- Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
- Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
- Siewert Type II Adenocarcinoma of Esophagogastric Junction
- Gastric Adenocarcinoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.